- Home
- APP vs VRTX Comparison
APP vs VRTX Comparison
Compare APP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- VRTX
- Stock Information
- Founded
- APP 2012
- VRTX 1989
- Country
- APP United States
- VRTX United States
- Employees
- APP N/A
- VRTX N/A
- Industry
- APP EDP Services
- VRTX EDP Services
- Sector
- APP Technology
- VRTX Technology
- Exchange
- APP Nasdaq
- VRTX Nasdaq
- Market Cap
- APP 127.6B
- VRTX 104.8B
- IPO Year
- APP 2021
- VRTX 1991
- Fundamental
- Price
- APP $415.31
- VRTX $484.24
- Analyst Decision
- APP Buy
- VRTX Buy
- Analyst Count
- APP 20
- VRTX 25
- Target Price
- APP $398.05
- VRTX $505.61
- AVG Volume (30 Days)
- APP 6.1M
- VRTX 1.5M
- Earning Date
- APP 02-12-2025
- VRTX 02-10-2025
- Dividend Yield
- APP N/A
- VRTX N/A
- EPS Growth
- APP 363.16
- VRTX N/A
- EPS
- APP 4.53
- VRTX N/A
- Revenue
- APP $4,709,248,000.00
- VRTX $11,020,100,000.00
- Revenue This Year
- APP $22.06
- VRTX $9.62
- Revenue Next Year
- APP $21.45
- VRTX $9.25
- P/E Ratio
- APP $91.59
- VRTX N/A
- Revenue Growth
- APP 43.44
- VRTX 11.66
- 52 Week Low
- APP $57.09
- VRTX $377.85
- 52 Week High
- APP $525.15
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- APP 53.47
- VRTX 65.58
- Support Level
- APP $366.96
- VRTX $451.99
- Resistance Level
- APP $519.79
- VRTX $469.55
- Average True Range (ATR)
- APP 32.08
- VRTX 11.70
- MACD
- APP 4.65
- VRTX 0.97
- Stochastic Oscillator
- APP 37.57
- VRTX 83.48
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.